The complete history of GLP-1 drugs — from 1902 incretin research to exenatide (2005), Victoza (2010), Ozempic (2017), Rybelsus (2019), Wegovy (2021), Mounjaro (2022), Zepbound (2023), and pipeline candidates retatrutide and orforglipron — with where PlexusDx Semaglutide, Tirzepatide, Microdose, and GLP-Squared protocols fit in 2026.

GLP-3 retatrutide explained: triple-agonist mechanism, Phase 3 TRIUMPH data, dysesthesia signal, FDA timeline, and how PlexusDx’s currently-available compounded semaglutide and tirzepatide protocols compare to the pipeline asset.

Retatrutide (Lilly's investigational triple agonist) and orforglipron (Lilly's oral non-peptide GLP-1) are the two big pipeline stories in 2026 — but neither is FDA-approved yet. Here's the realistic timeline, the Phase 3 data, the announced and unknown pricing, and how PlexusDx's currently-available compounded semaglutide and tirzepatide protocols ($129–$509/mo) compare for someone who needs an option today rather than in 2028.

Retatrutide access as of April 2026: this article covers the legitimate prescribing pathway, how telehealth evaluation works, red flags for unauthorized sellers, compounded alternatives through licensed 503A pharmacies, and PlexusDx Weight Management Protocols with provider evaluation included.

Tirzepatide and Retatrutide are widely compared GLP-1 pathway compounds. This head-to-head covers mechanism, FDA status, trial evidence, boxed-warning safety, April 2026 list pricing, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape baseline GLP-1 biology.

Retatrutide overview: this article covers what it is, how it works mechanically, FDA-approved indications, common and serious side effects including the class boxed-warning context, April 2026 cost landscape, and the FTO, GLP1R, MC4R, and TCF7L2 variants that shape every GLP-1 response.

Retatrutide list price is not commercially available — investigational only; no FDA-approved retail pricing exists as of April 2026. This article covers manufacturer savings programs, insurance coverage notes, compounded alternatives, and the PlexusDx Weight Management Protocols collection — all as of April 2026.

There is no FDA-approved "GLP-3" as of April 2026. Searches for it usually reflect interest in triple-agonist investigational compounds (retatrutide) or confusion with dual-agonist tirzepatide. This article explains what is real and the GLP-1 pathway genetics.

Retatrutide and tirzepatide are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Retatrutide (retatrutide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Retatrutide has an FDA-approved dosing structure with graduated titration. This article covers the label-level dose range, administration format, and titration concept — clinical decisions belong with a qualified healthcare provider.